CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 196 enrolled
Drug / intervention
Seidivid Ferty4 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05473039
NCT05473039N/ACompleted
CompareCT.gov

OvoVid Study: Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality in Oocyte Donors. Double-blind Randomized Placebo-controlled Clinical Trial

SEID S.A.·interventional·Posted Jul 25, 2022·Updated Aug 13, 2025

In Brief

A clinical study evaluating Seidivid Ferty4 and Placebo for Reproductive Techniques, Assisted. Completed, enrolled 196 participants across 1 site.

Detailed Summary

This study evaluates the effect of pretreatment with a multivitamin supplement with probiotics (Seidivid Ferty4®) on oocyte retrieval in normo-responder patients undergoing controlled ovarian hyperstimulation (COH) for oocyte donation, considering both the total number of oocytes retrieved and the number of mature oocytes retrieved, that is, in metaphase II (MII).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReproductive Techniques, Assisted
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 25, 2022
Enrollment StartJul 11, 2022
Primary CompletionJul 1, 2024
Study CompletionDec 28, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.9 years ago

Interventions

Seidivid Ferty4dietary

The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.

Placeboother

The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.